Middle East & Africa Rare Hemophilia Factors Market Size & Outlook, 2030

Revenue, 2023 (US$M)

$12.9

Forecast, 2030 (US$M)

$21.0

CAGR, 2024 - 2030

7.2%

Report Coverage

Middle East & Africa

Middle East & Africa rare hemophilia factors market, 2018-2030 (US$M)

Related Markets

Global Rare Hemophilia Factors Industry Outlook

North America Rare Hemophilia Factors Market Outlook

Europe Rare Hemophilia Factors Market Outlook

Asia Pacific Rare Hemophilia Factors Market Outlook

Latin America Rare Hemophilia Factors Market Outlook

MEA rare hemophilia factors market highlights

The MEA rare hemophilia factors market generated a revenue of USD 12.9 million in 2023.
The market is expected to grow at a CAGR of 7.2% from 2024 to 2030.
In terms of segment, factor i was the largest revenue generating product in 2023.
Factor I is the most lucrative product segment registering the fastest growth during the forecast period.

MEA data book summary

Market revenue in 2023	USD 12.9 million
Market revenue in 2030	USD 21.0 million
Growth rate	7.2% (CAGR from 2023 to 2030)
Largest segment	Factor i
Fastest growing segment	Factor I
Historical data covered	2018 - 2022
Base year for estimation	2023
Forecast period covered	2024 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Factor I
Key market players worldwide	Novo Nordisk A/S ADR, Biogen Inc, Bayer AG, Pfizer Inc, Takeda Pharmaceutical Co Ltd, Baxalta, CSL Ltd, Bio Products Laboratory

Other key industry trends

In terms of revenue, MEA region accounted for 4.1% of the global rare hemophilia factors market in 2023.
Globally, North America is projected to lead the regional market in terms of revenue in 2030.
Asia Pacific is the fastest growing regional market and is projected to reach USD 105.5 million by 2030.

No credit card required*

Horizon in a snapshot

30K+ Global Market Reports
120K+ Country Reports
1.2M+ Market Statistics
200K+ Company Profiles
Industry insights and more

Rare Hemophilia Factors Market Scope

Rare hemophilia factors market segmentation & scope

Product

Factor I

Factor II

Factor V

Factor VII

Factor X

Factor XI

Factor XIII

Drug Type

Factor Concentrates

Fresh Frozen Plasma

Cryoprecipitate

Others

Regions

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Countries

U.S.

Canada

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Japan

China

India

Australia

South Korea

Thailand

Mexico

Brazil

South Africa

Saudi Arabia

Argentina

UAE

Kuwait

Rare Hemophilia Factors Market Companies

Name	Profile	# Employees	HQ	Website

Middle East & Africa rare hemophilia factors market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare hemophilia factors market will help companies and investors design strategic landscapes.

Factor i was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Middle East & Africa rare hemophilia factors market based on factor i covering the revenue growth of each sub-segment from 2018 to 2030.

Reasons to subscribe to Middle East & Africa rare hemophilia factors market databook:

Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Middle East & Africa rare hemophilia factors market databook

Our clientele includes a mix of rare hemophilia factors market companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa rare hemophilia factors market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa rare hemophilia factors market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list